PROSERA:
Brief description of study
Phase 3 study to evaluate the efficacy and safety of oral inhalation GB002 seralutinib for the treatment of pulmonary arterial hypertension (PAH). GB002 is a powder taken by inhalation twice a day. The drug is absorbed into the lungs. GB002 will be inhaled using an approved, hand-held device called a dry powder inhaler. Study procedures include cardiovascular and pulmonary tests and up to 12 visits to the clinic and at least 2 telephone calls.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
